Bayesian Capital Management, LP Acadia Pharmaceuticals Inc Transaction History

Bayesian Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$14.62 - $18.42 $526,320 - $663,120	36,000 New	36,000 $585,000
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $5,998 - $8,644	337 Added 2.93%	11,837 $283,000
Q1 2023 May 15, 2023	BUY	$16.32 - $20.92 $187,680 - $240,580	11,500 New	11,500 $216,000
Q2 2022 Aug 15, 2022	BUY	$13.01 - $27.22 $542,464 - $1.13 Million	41,696 New	41,696 $587,000
Q1 2020 May 15, 2020	SELL	$31.65 - $46.87 $186,735 - $276,533	-5,900 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$36.21 - $51.4 $213,639 - $303,260	5,900 New	5,900 $252,000
Q4 2017 Feb 12, 2018	SELL	$26.84 - $39.14 $686,674 - $1 Million	-25,584 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $754,472 - $981,658	25,584	25,584 $964,000

281

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.71B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.